Statement from FDA on continuing efforts to maintain its strong oversight of generic drugs
date:Feb 25, 2019
At the FDA, protecting patient and consumer health is our highest priority. Assessing and mitigating risks is at the heart of everything we do across our vast portfolio. Sometimes the actions we take are visible, like warning letters or recalls. At other times, our actions to protect consumers are less discernable, but equally vital. Analyzing and addressing potential risks is a complex effort based on data and grounded in science. These activities are at the center of our consumer protection mi
1/35 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/15 21:48